carbonic acid-(4-methoxybenzyl)ester | 298701-35-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbonic acid-(4-methoxybenzyl)ester
• 英文别名: (4-Methoxyphenyl)methyl hydrogen carbonate
• CAS: 298701-35-6
• 化学式: C₉H₁₀O₄
• 分子量: 182.176
• InChiKey: HZFLPRPFCHEBPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.7±44.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  carbonic acid-(4-methoxybenzyl)ester 、 4-氨基-2,4-二氢-5-(4-甲氧基苯基)-3H-1,2,4-三唑-3-硫酮 在 三氯氧磷 作用下， 生成
  参考文献：
  名称：

  Triazolothiadiazoles and triazolothiadiazines as potent α-glucosidase inhibitors: Mechanistic insights from kinetics studies, molecular docking and dynamics simulations

  摘要：

  DOI：

  10.1016/j.ijbiomac.2023.126227

文献信息

• HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
  申请人：Academia Sinica

  公开号：US20160102116A1

  公开（公告）日：2016-04-14

  Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.

  糖脂类脂质（GSLs）的组成和诱导化学因子独立于iNKT的方法被揭示。
• METHOD OF SYNTHESIZING SUGAR CHAIN
  申请人：MITSUBISHI CHEMICAL CORPORATION

  公开号：EP1640379A1

  公开（公告）日：2006-03-29

  An object of the present invention is to provide a method for efficiently chemically synthesizing biomolecules including a nucleotide (nucleic acid), a peptide (protein), or a sugar chain, as representative examples. The present invention provides a method of solid-phase synthesis of sugar chain(s) for synthesizing multiple types of sugar chains in at least one sugar chain synthesis reaction system comprising multiple types of monosaccharide units, which is characterized in that it comprises changing the temperature in the sugar chain synthesis reaction system depending on the temperature rising rate that has been determined based on a decrease in side reaction(s) in the reaction system as an indicator.

  本发明的目的是提供一种有效地化学合成生物分子的方法，包括核苷酸（核酸）、肽（蛋白质）或糖链等代表性示例。本发明提供了一种固相合成糖链的方法，用于在至少一个糖链合成反应系统中合成多种类型的糖链，其特征在于根据已确定的反应系统中副反应减少的指标，改变糖链合成反应系统中的温度上升速率。
• [EN] NUCLEIC ACID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS DE TYPE ACIDE NUCLÉIQUE ET LEURS UTILISATIONS
  申请人：TRANSLATE BIO MA INC

  公开号：WO2018013525A1

  公开（公告）日：2018-01-18

  Provided herein are conjugates comprising targeting moieties such as sugars, folates and cell-penetrating peptides, which can be used for the improved delivery of agents (e.g., nucleic acids, such as oligonucleotides or mRNAs, or other agents) to cells. The invention provides conjugates and compounds comprising targeting moieties, methods for preparing the same, and intermediates useful in their preparation. In another aspect, the present invention provides formulations (e.g., pharmaceutical compositions) comprising the targetting moiety-containing conjugates and compounds. The present invention also provides methods for delivering agents (e.g., nucleic acids such as oligonucleotides or mRNAs) to a cell, methods for treating and/or preventing a disease or condition in a subject, and methods for modulating gene expression in a cell or a subject. Further, provided herein are kits comprising the conjugates, or formulations thereof; and kits for the preparation of conjugates described herein.

  本文提供了包含靶向基团的共轭物，如糖类、叶酸和穿膜肽，可用于改善药物（例如核酸，如寡核苷酸或mRNA，或其他药物）对细胞的传递。该发明提供了包含靶向基团的共轭物和化合物，以及其制备方法和制备过程中有用的中间体。另一方面，本发明提供了包含靶向基团的共轭物和化合物的配方（例如，药物组合物）。本发明还提供了将药物（例如核酸，如寡核苷酸或mRNA）传递至细胞的方法，用于治疗和/或预防受试者疾病或状况的方法，以及用于调节细胞或受试者基因表达的方法。此外，本文提供了包含这些共轭物或其配方的试剂盒；以及用于制备本文所述共轭物的试剂盒。
• [EN] DRUG ANTIBODY CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-ANTICORPS
  申请人：PHARMA MAR SA

  公开号：WO2021214126A1

  公开（公告）日：2021-10-28

  Drug conjugates having formula [D-(X)b-(AA)w-(T)g-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to (X)b if any, or (AA)w if any, or to (T)g if any, or (L); that are useful in the treatment of cancer.

  药物偶联物具有公式[D-(X)b-(AA)w-(T)g-(L)-]n-Ab，其中：D是具有以下公式(I)或药用可接受盐、酯、溶剂化物、互变异构体或立体异构体的药物部分，(I)其中D通过羟基或胺基与(X)b（如果有）、或(AA)w（如果有）、或(T)g（如果有）或(L)共价连接；在癌症治疗中有用。
• [EN] PROCESS FOR DEOXYFLUORINATION OF PHENOLS<br/>[FR] PROCÉDÉ DE DÉSOXYFLUORATION DE PHÉNOLS
  申请人：STUDIENGESELLSCHAFT KOHLE MBH

  公开号：WO2019025137A1

  公开（公告）日：2019-02-07

  The present invention refers to a process for transition-meta!-assisted 18F- deoxyfluorination of phenols. The transformation benefits from readily available phenols as starting materials; tolerance of moisture and ambient atmosphere, large substrate scope, and translatability to generate doses appropriate for positron emission tomography (PET) imaging.

  本发明涉及一种过渡金属催化的18F-脱氧氟化酚的过程。这种转化得益于容易获得的酚作为起始材料；能够容忍水分和大气环境，具有广泛的底物范围，并且可以转化为适合正电子发射断层扫描（PET）成像的剂量。